Blog Big Molecule Watch May 27, 2022

Deal Watch: Henlius Licenses Rituximab and Trastuzumab Products to Abbott in Brazil

Earlier this week, Shanghai Henlius Biotech, Inc. announced that it has entered into a semi-exclusive license agreement with Abbott Operations Uruguay S.R.L. for the commercialization of HANLIKANG (rituximab) and HANQUYOU (trastuzumab, trade name in Europe: Zercepac®), two products developed by Henlius, in Brazil.  According to the announcement, Abbott will pay Henlius an up-front fee of $3 million (USD), and up to an aggregate of $1.4 million (USD) for certain regulatory milestone payments.  Henlius states that the agreement “will help the company to further expand the overseas market of” the two products subject to the license.

About HANLIKANG


HANLIKANG (rituximab), a rituximab biosimilar independently developed by the Company, which was approved for commercialisation by National Medical Products Administration (“NMPA”) in February 2019.

About HANQUYOU


HANQUYOU (trastuzumab, trade name in Europe: Zercepac®) , a trastuzumab biosimilar independently developed by the Company, which was approved for commercialisation in all EU Member States, Iceland, Liechtenstein and Norway and Chinese Mainland by the European Commission (EC) and NMPA in July 2020 and August 2020, respectively.

The post Deal Watch: Henlius Licenses Rituximab and Trastuzumab Products to Abbott in Brazil appeared first on Big Molecule Watch.